Neuroactive steroids for the treatment of status epilepticus

Michael A Rogawski, Carlos M. Loya, Kiran Reddy, Dorota Zolkowska, Christoph Lossin

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Benzodiazepines are the current first-line standard-of-care treatment for status epilepticus but fail to terminate seizures in about one third of cases. Synaptic GABAA receptors, which mediate phasic inhibition in central circuits, are the molecular target of benzodiazepines. As status epilepticus progresses, these receptors are internalized and become functionally inactivated, conferring benzodiazepine resistance, which is believed to be a major cause of treatment failure. GABAA receptor positive allosteric modulator neuroactive steroids, such as allopregnanolone, also potentiate synaptic GABAA receptors, but in addition they enhance extrasynaptic GABAA receptors that mediate tonic inhibition. Extrasynaptic GABAA receptors are not internalized, and desensitization of these receptors does not occur during continuous seizures in status epilepticus models. Here we review the broad-spectrum antiseizure activity of allopregnanolone in animal seizure models and the evidence for its activity in models of status epilepticus. We also demonstrate that allopregnanolone inhibits ongoing behavioral and electrographic seizures in a model of status epilepticus, even when there is benzodiazepine resistance. Parenteral allopregnanolone may provide an improved treatment for refractory status epilepticus.

Original languageEnglish (US)
Pages (from-to)93-98
Number of pages6
JournalEpilepsia
Volume54
Issue numberSUPPL. 6
DOIs
StatePublished - 2013

Fingerprint

Status Epilepticus
Pregnanolone
GABA-A Receptors
Steroids
Benzodiazepines
Seizures
Neurotransmitter Receptor
Standard of Care
Treatment Failure
Animal Models

Keywords

  • Allopregnanolone
  • Allosteric modulator
  • Extrasynaptic GABAA receptor
  • Neurosteroid
  • Refractory status epilepticus
  • Seizure

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Rogawski, M. A., Loya, C. M., Reddy, K., Zolkowska, D., & Lossin, C. (2013). Neuroactive steroids for the treatment of status epilepticus. Epilepsia, 54(SUPPL. 6), 93-98. https://doi.org/10.1111/epi.12289

Neuroactive steroids for the treatment of status epilepticus. / Rogawski, Michael A; Loya, Carlos M.; Reddy, Kiran; Zolkowska, Dorota; Lossin, Christoph.

In: Epilepsia, Vol. 54, No. SUPPL. 6, 2013, p. 93-98.

Research output: Contribution to journalArticle

Rogawski, MA, Loya, CM, Reddy, K, Zolkowska, D & Lossin, C 2013, 'Neuroactive steroids for the treatment of status epilepticus', Epilepsia, vol. 54, no. SUPPL. 6, pp. 93-98. https://doi.org/10.1111/epi.12289
Rogawski, Michael A ; Loya, Carlos M. ; Reddy, Kiran ; Zolkowska, Dorota ; Lossin, Christoph. / Neuroactive steroids for the treatment of status epilepticus. In: Epilepsia. 2013 ; Vol. 54, No. SUPPL. 6. pp. 93-98.
@article{9f68dc83707b4cc1b73434a74049addf,
title = "Neuroactive steroids for the treatment of status epilepticus",
abstract = "Benzodiazepines are the current first-line standard-of-care treatment for status epilepticus but fail to terminate seizures in about one third of cases. Synaptic GABAA receptors, which mediate phasic inhibition in central circuits, are the molecular target of benzodiazepines. As status epilepticus progresses, these receptors are internalized and become functionally inactivated, conferring benzodiazepine resistance, which is believed to be a major cause of treatment failure. GABAA receptor positive allosteric modulator neuroactive steroids, such as allopregnanolone, also potentiate synaptic GABAA receptors, but in addition they enhance extrasynaptic GABAA receptors that mediate tonic inhibition. Extrasynaptic GABAA receptors are not internalized, and desensitization of these receptors does not occur during continuous seizures in status epilepticus models. Here we review the broad-spectrum antiseizure activity of allopregnanolone in animal seizure models and the evidence for its activity in models of status epilepticus. We also demonstrate that allopregnanolone inhibits ongoing behavioral and electrographic seizures in a model of status epilepticus, even when there is benzodiazepine resistance. Parenteral allopregnanolone may provide an improved treatment for refractory status epilepticus.",
keywords = "Allopregnanolone, Allosteric modulator, Extrasynaptic GABAA receptor, Neurosteroid, Refractory status epilepticus, Seizure",
author = "Rogawski, {Michael A} and Loya, {Carlos M.} and Kiran Reddy and Dorota Zolkowska and Christoph Lossin",
year = "2013",
doi = "10.1111/epi.12289",
language = "English (US)",
volume = "54",
pages = "93--98",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Neuroactive steroids for the treatment of status epilepticus

AU - Rogawski, Michael A

AU - Loya, Carlos M.

AU - Reddy, Kiran

AU - Zolkowska, Dorota

AU - Lossin, Christoph

PY - 2013

Y1 - 2013

N2 - Benzodiazepines are the current first-line standard-of-care treatment for status epilepticus but fail to terminate seizures in about one third of cases. Synaptic GABAA receptors, which mediate phasic inhibition in central circuits, are the molecular target of benzodiazepines. As status epilepticus progresses, these receptors are internalized and become functionally inactivated, conferring benzodiazepine resistance, which is believed to be a major cause of treatment failure. GABAA receptor positive allosteric modulator neuroactive steroids, such as allopregnanolone, also potentiate synaptic GABAA receptors, but in addition they enhance extrasynaptic GABAA receptors that mediate tonic inhibition. Extrasynaptic GABAA receptors are not internalized, and desensitization of these receptors does not occur during continuous seizures in status epilepticus models. Here we review the broad-spectrum antiseizure activity of allopregnanolone in animal seizure models and the evidence for its activity in models of status epilepticus. We also demonstrate that allopregnanolone inhibits ongoing behavioral and electrographic seizures in a model of status epilepticus, even when there is benzodiazepine resistance. Parenteral allopregnanolone may provide an improved treatment for refractory status epilepticus.

AB - Benzodiazepines are the current first-line standard-of-care treatment for status epilepticus but fail to terminate seizures in about one third of cases. Synaptic GABAA receptors, which mediate phasic inhibition in central circuits, are the molecular target of benzodiazepines. As status epilepticus progresses, these receptors are internalized and become functionally inactivated, conferring benzodiazepine resistance, which is believed to be a major cause of treatment failure. GABAA receptor positive allosteric modulator neuroactive steroids, such as allopregnanolone, also potentiate synaptic GABAA receptors, but in addition they enhance extrasynaptic GABAA receptors that mediate tonic inhibition. Extrasynaptic GABAA receptors are not internalized, and desensitization of these receptors does not occur during continuous seizures in status epilepticus models. Here we review the broad-spectrum antiseizure activity of allopregnanolone in animal seizure models and the evidence for its activity in models of status epilepticus. We also demonstrate that allopregnanolone inhibits ongoing behavioral and electrographic seizures in a model of status epilepticus, even when there is benzodiazepine resistance. Parenteral allopregnanolone may provide an improved treatment for refractory status epilepticus.

KW - Allopregnanolone

KW - Allosteric modulator

KW - Extrasynaptic GABAA receptor

KW - Neurosteroid

KW - Refractory status epilepticus

KW - Seizure

UR - http://www.scopus.com/inward/record.url?scp=84891501302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891501302&partnerID=8YFLogxK

U2 - 10.1111/epi.12289

DO - 10.1111/epi.12289

M3 - Article

C2 - 24001085

AN - SCOPUS:84891501302

VL - 54

SP - 93

EP - 98

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 6

ER -